What did Iperion Limited announce?

Iperion Limited (NZX: IPR) filed “2026 Annual Report” with NZX on 30 June 2026, as an annual report announcement.

From the announcement:“Financial Results The Company reported a net loss attributable to shareholders of $294,595 for the year. This compares with a net loss attributable to shareholders of $455,683 for the previous year.”
When was it filed?
30 June 2026
Where is the original?
NZX announcement
Iperion Limited/Announcement
Iperion Limited logo

2026 Annual Report

Annual Report30 June 2026IPRReal Estate

IPERION LIMITED





FOR THE YEAR ENDED 31 MARCH 2026



ANNUAL REPORT

Page 1 Iperion Limited Annual Report 31 March 2026

CONTENTS


DIRECTORS’ REPORT ________________________________________________________________ 2

DIRECTORS' RESPONSIBILITY STATEMENT ________________________________________________ 4

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME _______________________ 5

STATEMENT OF FINANCIAL POSITION ___________________________________________________ 6

STATEMENT OF CHANGES IN EQUITY ____________________________________________________ 7

STATEMENT OF CASH FLOWS __________________________________________________________ 8

NOTES TO THE FINANCIAL STATEMENTS _________________________________________________ 9

INDEPENDENT AUDITOR’S REPORT ____________________________________________________ 24

CORPORATE GOVERNANCE STATEMENT ________________________________________________ 27

ADDITIONAL INFORMATION _________________________________________________________ 31

BUSINESS DIRECTORY ______________________________________________________________ 35













IPERION Limited
Page 2 Iperion Limited Annual Report 31 March 2026

DIRECTORS’ REPORT


Dear Shareholders


The Directors of Iperion Limited (“the Company” or “Iperion”) are pleased to report its financial results for the

year ended 31 March 2026.


Financial Results

The Company reported a net loss attributable to shareholders of $294,595 for the year. This compares with a net

loss attributable to shareholders of $455,683 for the previous year.


There was no sales income for the year. The improvement in result compared to the previous year is mainly a

result of discount received on the fixed outsourced manufacturing plant fee.


There were no manufacturing plant expenses for the year. The $400,000 annual fee for the fixed facility and

operating fees was fully discounted for the 2026 year in recognition of lower than expected production activity

and the plant being partially supported by research grants secured by the Operator on the ongoing development

in applications for the Pathoglaze® product.

Three Summit Ventures has also agreed to fully discount the agreed $400,000 annual fixed fee for the next two

financial years to March 2028.


Administrative expenses for the year were $294,605 decreasing by $23,176 on the prior year. Expenses remained

mostly in line with the previous year, except for higher stock exchange costs and lower costs on travel in the year.


License agreement

Iperion has the exclusive world wide licence for Pathoglaze. In recognition of the collaborative efforts

undertaken between the inventor of Pathoglaze and Iperion, agreement was reached to permanently waive the

customer and revenue performance targets under the license.


Operations and Product Development

Work undertaken has mainly focused on completing the development of Pathoglaze infused polymer jute bags

used for shipping cocoa and coffee beans. This work is being undertaken in collaboration with a multinational

chocolate manufacturer.


The Company continues to work toward securing long term sales agreements.


The Company has entered into a loan agreement Elitesoft Asia, a company related to Mr Chang Ku EE, the

majority shareholder and a director of the Company, pursuant to which Elitesoft provides a loan facility of

$250,000 to the Company at 8% interest (Hong Kong Monetary Authority Base Rate + 4%), which can be

IPERION Limited
Page 3 Iperion Limited Annual Report 31 March 2026

Directors Report - Continued

increased to US$1,000,000 subject to approval by Iperion’s shareholders. This loan replaces the NZ$150,000 loan

facility from Mr EE announced on 15 June 2026. In addition, Mr EE has also confirmed that he will provide

financial support to the Company, if required to meet its working capital obligations and liabilities as they fall due,

for at least a period of 12 months from the date of approval of the Company’s financial statements.

To provide further support to cash flow capacity, directors agreed to defer 50% of directors’ fees and 33% of the

management fee commencing from January 2026, until sufficient sales are achieved to move the company to a

positive cash flow position.

Based on an approved base case forecast with no sales and utilizing the loan facility, the Company has sufficient

cash reserves to cover its costs over the next 12 months.


On behalf of the Directors of Iperion the Company extends its thanks to the shareholders for their support of the

Company.

IPERION Limited
Page 4 Iperion Limited Annual Report 31 March 2026

DIRECTORS' RESPONSIBILITY STATEMENT


The Directors of Iperion Limited are pleased to present to shareholders the financial statements for

Iperion Limited for the year ended 31 March 2026.

The Directors are responsible for presenting financial statements in accordance with New Zealand law

and generally accepted accounting practice, which give a true and fair view of the financial position of

the Company as at 31 March 2026 and the results of its operations and cash flows for the year ended

on that date.

The Directors consider the financial statements of the Company have been prepared using accounting

policies which have been consistently applied and supported by reasonable judgements and estimates

and that all relevant financial reporting and accounting standards have been followed.

The Directors believe that proper accounting records have been kept which enable with reasonable

accuracy, the determination of the financial position of the Company and facilitate compliance of the

financial statements with the Financial Reporting Act 2013.

The Directors consider that they have taken adequate steps to safeguard the assets of the Company,

and to prevent and detect fraud and other irregularities. Internal control procedures are also

considered to be sufficient to provide a reasonable assurance as to the integrity and reliability of the

financial statements.

The Financial Statements are signed on behalf of the Board by:




Director: Bruce Dunlop Director: John Cilliers


30 June 2026



IPERION Limited
Page 5 Iperion Limited Annual Report 31 March 2026

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE

INCOME







The accompanying notes form part of these financial statements

For the year ended 31 March 2026

YearYear

20262025

Notes$$

Interest Income - financial asset at amortised cost10 20,382

Outsourced manufacturing plant expenses2- (150,000)

Administrative expenses3(294,605) (317,781)

Depreciation, amortisation and impairment9- (8,284)

(294,595) (455,683)

Finance costs- -

Loss before income tax(294,595) (455,683)

Income tax benefit4- -

Net loss for the period attributable to shareholders(294,595) (455,683)

Other comprehensive income- -

(294,595) (455,683)

Earnings per share:centscents

Basic and diluted loss per share6(0.0572) (0.0885)

Loss before interest and tax

Total comprehensive loss for the period attributable to shareholders

IPERION Limited
Page 6 Iperion Limited Annual Report 31 March 2026

STATEMENT OF FINANCIAL POSITION



For and on behalf of the Board of Directors, dated 30 June 2026



Director: Bruce Dunlop Director: John Cilliers


The accompanying notes form part of these financial statements

As at 31 March 2026

Year

Year

2026

2025

Notes

$

$

Assets

Current assets

Cash and cash equivalents

7

155,492



425,341



GST receivable

1,196



1,384



Income tax receivable (RWT)

7,563



7,563



164,251



434,288



Non-current assets

NZX Deposit

8

20,000



20,000



20,000



20,000



Total assets

184,251



454,288



Equity and liabilities

Current liabilities

Trade and other payables

10

130,448



105,890



Total liabilities

130,448



105,890



Equity

Issued capital

5

5,672,856



5,672,856



Accumulated loss

(5,619,053)



(5,324,458)



Total equity

53,803



348,398



Total equity and liabilities

184,251



454,288


IPERION Limited
Page 7 Iperion Limited Annual Report 31 March 2026

STATEMENT OF CHANGES IN EQUITY




The accompanying notes form part of these financial statements



For the year ended 31 March 2026

Issued

capital

Accumulated

LossTotal equity

Notes$$$

As at 1 April 20255,672,856 (5,324,458) 348,398

Loss for the year- (294,595) (294,595)

Total comprehensive income- (294,595) (294,595)

At 31 March 202655,672,856 (5,619,053) 53,803

As at 1 April 20245,672,856 (4,868,775) 804,081

Loss for the year- (455,683) (455,683)

Total comprehensive income- (455,683) (455,683)

At 31 March 202555,672,856 (5,324,458) 348,398

IPERION Limited
Page 8 Iperion Limited Annual Report 31 March 2026

STATEMENT OF CASH FLOWS





The accompanying notes form part of these financial statements








For the year ended 31 March 2026

YearYear

20262025

$$

Operating activities

10 20,382

Payments to suppliers(270,047) (454,996)

Net GST refunds (paid)/received188 (2,709)

Income tax paid- (7,563)

Income tax refund received- 12,030

Net cash outflows from operating activities(269,849) (432,856)

Investing activities

Purchase of intangible assets- (8,284)

- 697,834

Net cash inflows from investing activities- 689,550

Net (decrease)/increase in cash and cash equivalents(269,849) 256,694

Cash and cash equivalents at beginning of year425,341 168,647

Cash and cash equivalents at end of year155,492 425,341

Interest received

Cash received from maturity of term deposit

IPERION Limited

Page 9 Iperion Limited Annual Report 31 March 2026

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2026


1. STATEMENT OF ACCOUNTING POLICIES

Reporting entity and statement of compliance

These financial statements and notes represent those of Iperion Limited (the “Company” or “Iperion”).

Iperion Limited is a limited liability company incorporated and domiciled in New Zealand. It is registered under

the Companies Act 1993. Iperion is listed on the NZX Main Board (“NZSX”). Iperion is a FMC reporting entity

under Part 7 of the Financial Markets Conduct Act 2013 and its financial statements have been prepared in

accordance with the Companies Act 1993, The Financial Reporting Act 2013 and the Financial Markets Conduct

Act 2013 and the NZX Main Board Listing Rules.

As at 31 March 2026 the Company is undertaking marketing and commercialisation of its product, Pathoglaze, an

antimicrobial compound.

The registered office and principal place of business are disclosed in the directory to the annual report.

Basis of preparation

The financial statements have been prepared in accordance with Generally Accepted Accounting Practice in New

Zealand (NZ GAAP). The company is a for-profit entity for the purposes of complying with NZ GAAP. The financial

statements comply with New Zealand equivalents to International Financial Reporting Standards (NZ IFRS) and

IFRS® Accounting Standards.

The information is presented in New Zealand dollars which is the Company’s functional currency and

presentation currency and is rounded to the nearest dollar.

Measurement base

The accounting principles adopted are those recognised as appropriate for the measurement and reporting of

financial performance and financial position on the historical cost basis.

Use of estimates and judgements

The preparation of financial statements in conformity with NZ IFRS requires management to make judgements,

estimates and assumptions that affect the application of accounting policies and the reported amounts of assets,

liabilities, income and expenses.

The estimates and associated assumptions are based on historical experience and various other factors that are

believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates

and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised

in the year in which the estimates are revised and in any future periods affected.


Page 10 Iperion Limited Annual Report 31 March 2026

Deferred Tax Asset

A deferred tax asset of $663,347 (2025: $583,179) has not been recognized in the Statement of Financial Position

(note 4). The operations of the antimicrobial manufacturing operations are still in the startup stage and

production and sales activities have not commenced. As such uncertainty remains that taxable profit will be

available against which the deductible temporary differences and carry-forward of unused tax losses can be

utilised. Deferred tax asset will only be recognised when the Company commences business activities that

provide a taxable profit.


Impairment of Trademarks

The Company has registered a trademark in New Zealand and registration in other countries continues. The

trademark registration period ends in 2033 and can be renewed at the end of each registration period. The

trademark is an indefinite life intangible. The Company is yet to commence sales of the products related to the

trademark and as such future cash flows cannot be forecasted reliably. Neither can the recoverable value of the

intangible asset given the unique nature of the product and its novelty to the market. As such management have

determined that the recoverable value of the trademark at 31 March 2026 is $Nil and that it be fully impaired

(note 9).


Other than Going Concern (note 16), there were no other significant judgements and estimates in 2025 or 2026.


Material accounting policies

The following material accounting policies, which materially affect the measurement of financial performance

and financial position, have been applied.

a) Goods and services tax

All amounts are shown exclusive of Goods and Services Tax (GST), except for receivables and payables that are

stated inclusive of GST.

b) Adoption of new and revised standards

Changes in accounting policies

There are no NZ IFRS, NZ IFRIC interpretations or other applicable IFRS® Accounting Standards that are effective

for the first time for the financial year beginning on or after 1 April 2025 that had a material impact on the

financial statements.

New NZ IFRS Standards and Interpretations Issued but not yet adopted.

There are no new standards, amendments or interpretations that have been adopted or are not yet effective that

have a material impact on the company except for the below standard:


Page 11 Iperion Limited Annual Report 31 March 2026

The following amendments are effective for the period beginning 1 January 2026:

• Amendments to the Classification and Measurement of Financial Instruments – Amendments to NZ IFRS

9 Financial Instruments and NZ IFRS 7.

• Contracts Referencing Nature-dependent Electricity (Amendments to IFRS 9 and IFRS 7)

• Annual Improvements to IFRS Accounting Standards – Volume 11

The following amendments are effective for the period beginning 1 January 2027:

• NZ IFRS 18 Presentation and Disclosure in Financial Statements.

The company is currently assessing the effect of these new accounting standards and amendments.

NZ IFRS 18 Presentation and Disclosure in Financial Statements supersedes NZ IAS 1 and will result in major

consequential amendments to IFRS accounting Standards including NZ IAS 8 Basis of Preparation of Financial

Statements. Even though NZ IFRS 18 will not have any effect on the recognition and measurement of items in the

financial statements, it is expected to have a significant effect on the presentation and disclosure of certain items.

These changes include categorisation and sub-totals in the statement of profit or loss, aggregation/dis

aggregation and labelling of information and disclosure of management defined performance measures.

The accounting policies used in these financial statements have been applied consistently with those of the prior

year.

The company does not expect any other standards issued by the New Zealand Accounting Standards Board

(NZASB) or IASB, but not yet effective, to have a material impact on the company.


2. OUTSOURCED MANUFACTURING PLANT EXPENSES


The outsourced manufacturing plant expense consists of a fixed annual fee of $400,000 paid quarterly in advance

covering the rent and fixed costs of the fully equipped facility. The Company received a discount of $250,000 on

the fee for the 2025 year, and a full discount of $400,000 for the 2026 year, in recognition of lower than expected

production activity and the plant being partially supported by research grants secured by the operator for the

ongoing development in applications of the product. The annual fixed fee is fully discounted until March 2028

(note 17).

2026

2025

$

$

Outsourced manufacturing plant expenses

-



150,000



Page 12 Iperion Limited Annual Report 31 March 2026

3. ADMINISTRATION EXPENSES BY NATURE


The operating expenses generally relate to the cost associated with being a listed entity. Travel and

accommodation expenses for the current year were mainly in relation to sales and marketing activities.

*There were no other services provided to the Company by BDO Auckland.


4. TAXATION


2026

2025

$

$

Fees paid to BDO Auckland* - statutory audit

46,250



46,250



Fees paid to BDO Auckland* - statutory audit prior year

2,838



19,190



Contractors

13

42,737



44,302



Directors' fees

13

156,000



156,000



Travel and accommodation

6,396



25,335



Legal Fees

4,507



1,730



NZX Listing and registry costs

32,805



24,411



Other

3,072



563



294,605



317,781



2026

2025

$

$

Income tax benefit

Current tax

Current tax on loss for the year

(82,487)



(127,591)



Total current tax benefit

(82,487)



(127,591)



Deferred income tax

Increase in deferred tax assets [not yet recognised]

82,487



127,591



Total deferred tax benefit

82,487



127,591



Income tax benefit

-



-



Page 13 Iperion Limited Annual Report 31 March 2026

4. TAXATION - Continued

Numerical reconciliation of income tax expense to prima facie tax payable


Deferred tax asset

Company Losses to carry forward as at 31 March 2026 are $2,639,093 (2025: $2,082,781).

The deferred tax asset of $663,347 (2025: $583,179), resulting from carry forward tax losses, will only be

recognised when the Company commences business activities that provide a taxable profit (note 1).


Accounting policy: Taxation

The income tax expense or benefit for the period is the tax payable on the current period’s taxable income

adjusted by changes in deferred tax assets and liabilities attributed to temporary differences between the tax

base of assets and liabilities and their carrying amounts in the financial statements.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the

taxation authorities based on the current period’s taxable income. The tax rates and laws used to compute the

amount are those that are enacted or substantively enacted at reporting date.

Deferred tax assets and liabilities are recognised where the carrying amount of an asset or liability in the

statement of financial position differs from its tax base, except for differences arising on:

- The initial recognition of an asset or liability in a transaction which is not a business combination and at the

time of the transaction affects neither accounting or taxable profit, and

- Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profit will be

available against which the difference can be utilised.

The income tax expense or revenue attributable to amounts recognised directly in equity are also recognised

directly in equity.


2026

2025

$

$

Loss before tax

(294,595)



(455,683)



Prima facie income tax at 28%

(82,487)



(127,591)



Subtotal

(82,487)



(127,591)



Tax losses not recognised

82,487



127,591



Income tax benefit

-



-



Tax losses carried forward

2026

2025

$

$

Opening balance

2,082,781



1,636,381



This Year

294,595



455,683



Prior year adjustment

(8,283)



(9,283)



Closing balance

2,369,093



2,082,781



Page 14 Iperion Limited Annual Report 31 March 2026

5. SHARE CAPITAL

Share Capital


All ordinary shares have been fully paid and have equal voting and dividend rights. The shares have no par value.

No shares were issued or repurchased in the current or comparative years.

The Company’s capital is managed with the objectives of maintaining adequate working capital so that all

obligations can be met on time. All components of equity are regarded as “capital”. The company is not subject to

any externally imposed capital requirements.


6. EARNINGS PER SHARE AND NET TANGIBLE ASSETS

Earnings per share

At 31 March 2026 there were 514,894,500 shares on issue (2025: 514,894,500).


The Company does not currently have any dilutive interests.

Accounting policy: Earnings per share

The company presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is

calculated by dividing the profit or loss attributable to ordinary shareholders by the weighted average number of

ordinary shares outstanding during the year, adjusted for own shares held.

Diluted earnings/(loss) per share is determined by adjusting the profit or loss attributable to ordinary

shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive

potential ordinary shares.


Number of

Shares

Value in $

Balance at 31 March 2026

514,894,500



5,672,856



Balance at 31 March 2025

514,894,500



5,672,856



2026

2025

Loss for the year

[ $ ]

($294,595)

($455,683)

Weighted average number of shares

514,894,500



514,894,500



Basic loss per share

[ cents ]

(0.0572)



(0.0885)



Diluted average shares on issue

514,894,500



514,894,500



Diluted loss per share

[ cents ]

(0.0572)



(0.0885)



Page 15 Iperion Limited Annual Report 31 March 2026

6. EARNINGS PER SHARE AND NET TANGIBLE ASSETS - Continued

Net tangible assets

Net tangible assets per share is a non-GAAP measure that is required to be disclosed by the NZX Listing Rules.

The calculation of the net tangible assets per share and its reconciliation to the Statement of Financial Position is

presented below:





7. CASH AND TERM DEPOSITS

Cash and cash equivalents


Accounting policy: Cash and cash equivalents

For the purpose of the statement of cash flows, cash includes cash on hand, deposits at call and short term highly

liquid deposits with maturities of three months or less.


2026

2025

Total Assets

184,251



454,288



Less:

Total Li abi l i ti es

(130,448)



(105,890)



Net Tangi bl e Assets

[ $ ]

53,803



348,398



Shares i n i ssue

514,894,500



514,894,500



Net Tangi bl e Asset per share

[ cents ]

0.0104



0.0677



2026

2025

$

$

Cash and cash equivalents: Cash at bank

155,492



425,341



Page 16 Iperion Limited Annual Report 31 March 2026

8. NZX DEPOSIT


The deposit bond held at NZX is provided as security for all amounts payable to the NZX by the Company as an

Issuer and is provided in accordance with NZX Listing Rule 1.23.

Accounting policy: Other receivables

Other receivables are recognised initially at fair value and subsequently measured at amortised cost. The carrying

amount of the asset is reduced through the use of provision accounts, and the amount of the loss is recognised in

profit or loss within ‘Administration expenses’.



9. INTANGIBLE ASSETS


A total of $17,556 has been spent on establishment of the Pathoglaze trademark. Until sales are realized on the

product, the value of the trademark is considered to be fully impaired.

Accounting policy: Trademarks and Impairment

Trademarks are carried at original cost incurred at the date of acquisition. The trademarks represents the costs

incurred on the registration of the trade name Pathoglaze. The trademark has an indefinite life and is not

amortised. Instead, the trademark is tested for impairment annually or more frequently if events or changes in

circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses.

An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable

amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use.


2026

2025

$

$

Non Current:

Bond held at NZX

20,000



20,000



2026

2025

$

$

Trademarks

Opening net book value

-



-



Additions

-



8,284



Impairment loss

1

-



(8,284)



Closing net book value

-



-



Page 17 Iperion Limited Annual Report 31 March 2026

10. TRADE AND OTHER PAYABLES


Accounting policy: Trade and other payables

Trade and other payables are initially recognised at fair value net of directly attributable transaction costs and

thereafter carried at amortised cost and due to their short term nature they are not discounted. They represent

liabilities for goods and services provided to the Company by suppliers in the ordinary course of business prior to

the end of the financial year that are unpaid and arise when the Company become obliged to make future

payments in respect of the purchase of these goods and services. The amounts are unsecured, interest free and

are usually paid within normal business trading terms, except for related party payables that are payable on

demand.



11. RECONCILIATION OF OPERATING CASHFLOW AND REPORTED LOSS




2026

2025

$

$

Current:

Trade payables

4,843



2,785



Accrued expenses

68,750



46,250



Related party payables

13

56,855



56,855



130,448



105,890



20262025

$$

Net loss for the year(294,595) (455,683)

Add/(less) non cash items

Depreciation, amortisation and impairment9- 8,284

Changes in assets and liabilities

(Increase)/decrease in Net GST receivable188 (2,709)

(Increase)/decrease in current tax asset- 4,467

Increase/(decrease) in trade and other payables1024,558 12,785

Net cash ouflows from operating activities(269,849) (432,856)


Page 18 Iperion Limited Annual Report 31 March 2026

12. FINANCIAL INSTRUMENTS

The Company has entered into a number of non-derivative financial instruments all of which are classified as

financial assets and liabilities at amortised cost. The carrying values of these items approximate their fair value.

They are listed as follows:


All financial instruments are classified as current and have maturity dates of less than twelve months, other than

the NZX deposit which is repayable on delisting of Iperion from NZX main board.

The Company is subject to a number of financial risks.

Credit risk: Financial instruments that potentially subject the Company to credit risk are bank balances and short

term deposits. The maximum exposure to credit risk at reporting date is the value of the instruments as stated in

the Statement of Financial Position. The Company only places cash on deposit with Westpac Bank which has a

Standard & Poor’s credit rating of AA- rating.

Liquidity risk: Liquidity risk represents the company's ability to meet its contractual obligations as they fall due.

As at 31 March 2026, all financial liabilities have a contractual maturity of less than 3 months. Liquidity risk was

substantially eliminated by the cash and cash equivalents balance of $155,492 (2025: $425,341) in total. The

Board regularly reviews its liquidity position by examining future cash requirements.

Interest rate risk: Interest rate risk is the risk of loss to the Company arising from adverse changes in interest

rates. Cash at bank and short term deposits are subject to interest rate risk. Changes to interest rates can impact

the Company’s financial results by affecting the interest earned on these assets. There is no interest rate risk as

cash is held in an on call account to provide liquidity to support anticipated sales activities. The company does not

earn interest on cash in the on call account.


Accounting policy: Financial instruments

Financial instruments recognised in the statement of financial position include cash and cash equivalents, term

deposits, receivables and payables. The Company has no financial instruments that are not reported in the

Statement of Financial Position.


2026

2025

$

$

Financial assets at amortised cost

Cash and cash equivalents

7

155,492



425,341



NZX deposit

8

20,000



20,000



Total Financial assets

175,492



445,341



Financial liabilities at amortised cost

Trade and other payables

10

130,448



105,890



Total financial liabilities

130,448



105,890



Page 19 Iperion Limited Annual Report 31 March 2026

12. FINANCIAL INSTRUMENTS - Continued

Accounting policy: Financial instruments - continued

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual

provisions of the financial instruments.

A financial asset is derecognised when the contractual rights to cash flows from the financial asset expire, or

when the financial asset and all subsequent risks and rewards are transferred. A financial liability is derecognised

when it is extinguished, discharged, cancelled or expires.

Impairment of financial assets

The Company recognises a loss allowance for expected credit losses on receivables. The amount of expected

credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the

respective financial instrument.

Impairment provisions are recognised based on a forward looking expected credit loss model. The methodology

used to determine the amount of the provision is based on whether there has been a significant increase in credit

risk since initial recognition of the financial asset. For those where the credit risk has not increased significantly

since initial recognition of the financial asset, twelve month expected credit losses along with gross interest

income are recognised. For those for which credit risk has increased significantly, lifetime expected credit losses

along with the gross interest income are recognised. For those that are determined to be credit impaired, lifetime

expected credit losses (‘ECL’) along with interest income on a net basis are recognised.

Lifetime ECL represents the expected credit losses that will result from all possible default events over the

expected life of a financial instrument.

The Company recognises an impairment loss in profit or loss for all financial instruments with a corresponding

adjustment to their carrying amount. The carrying amount of the financial asset is reduced by the impairment

loss directly for all financial assets. Changes in the carrying amount of the allowance account are recognised in

profit or loss.

The Company writes off a financial asset when there is information indicating that there is no reasonable

expectation of recovery. For example, when the debtor has been placed under liquidation or has entered into

bankruptcy proceedings, or in the case of trade receivables, when the amounts are over one year past due,

whichever occurs sooner. Financial assets written off may still be subject to enforcement activities under the

Company’s recovery procedures, taking into account legal advice where appropriate. Any recoveries made are

recognised in profit or loss.



Page 20 Iperion Limited Annual Report 31 March 2026

13. RELATED PARTY TRANSACTIONS AND BALANCES

Remuneration

The directors are considered to be the key management personnel of the Company.

The following table provides the compensation for key management personnel and directors, all of which are

short term benefits.


* Management and professional fees is included in Contractors expenses note 3


Related party trade and other payables


* $100,000 was received during 2019 from Mr Chang Ku EE to cover the compliance costs associated with the

change in the majority shareholder from Golden Tower New Zealand Limited to Mr EE. Actual costs were less

than the payment received. The remaining balance of $56,855 is payable on demand, is unsecured and is

included in trade and other payables (note 10).

** In order to support cash flow capacity, directors agreed to defer 50% of directors fees and 30% of the

management fee commencing from January 2026, until sufficient sales are achieved to move the company to a

positive cash flow position.

The related party trade and other payables are interest free.

2026

2025

$

$

Management and professional services fees

42,737



44,302



Directors' fees

3

156,000



156,000



198,737



200,302



2026

2025

$

$

Payables for balance of funds received for shareholder transaction costs: *

Chang Ku EE (Director and majority shareholder)

56,855



56,855



Accruals for deferred director and management fees: **

Chang Ku EE (Director and majority shareholder)

6,000



-



KC NG (Director)

7,500



-



Bruce Dunlop (Director)

4,500



-



John Cilliers (Director)

4,500



-



79,355



56,855



Page 21 Iperion Limited Annual Report 31 March 2026

RELATED PARTY TRANSACTIONS AND BALANCES - Continued

Transactions: 2026

There were no transactions with related parties during the year, other than compensation paid to directors or

their nominees, as disclosed above.

Transactions: 2025

There were no transactions with related parties during the year, other than compensation paid to directors as

disclosed above.

14. SEGMENT INFORMATION

As at 31 March 2026, the company is organised into one operating segment and one geographical segment in

New Zealand. The Operating segments are reported in a manner consistent with the internal reporting provided

to the chief operating decision maker. The chief operating decision maker is the Board of Directors.

15. COMMITMENTS AND CONTINGENT LIABILITIES

The antimicrobial license agreement, including subsequent variations, contains minimum performance targets

that set minimum royalty of 2.1% to be paid on revenue of SGD $150,000 by 30 September 2026 and 2.1% on

revenue of SGD $1m annually from 30 September 2027. Subsequent to year end, the parties have agreed that

the minimum performance targets under the license agreement be permanently waived in accordance with a

License Fee Variation Agreement, dated 26 June 2026.

In accordance with the terms of the Pilot Outsourcing Agreement entered on 20 January 2023 for the

commercialization of antimicrobial coatings, the Company will pay fixed fees of NZD$400,000 per annum towards

the setup of the facility, engagement of core personnel and subsequent services, as well as commission of 30% on

gross profit. Invoices under the Pilot Outsourcing Agreement are payable in 30-day instalments. However, the

Company has the ability to terminate the Pilot Outsourcing Agreement at any time, with prior notice to the

Licensor, with no break fees. The Vendor agreed to discount $250,000 of the fees for the year ending 31 March

2025 (note 2) and the full $400,000 annual fee for the financial year ending 31 March 2027. Subsequent to year

end, the Vendor has agreed to fully discount the annual fees until 31 March 2028.

There were no other capital commitments or contingent liabilities at 31 March 2026 (2025: $Nil).

16. GOING CONCERN

The Directors have concluded that the basis of preparation of the financial statements on a going concern basis is

appropriate.

The Company has not earned revenue for the year ended 31 March 2026 from its product, Pathoglaze.

Commercialization activities continue, but due to the nature of the product, which requires it to be incorporated

into customers’ product manufacturing processes, the time required for sales conversions is long. The Company

reported a loss of $294,595 (2025: $455,683) from continuing operations for the year ended 31 March 2026. As

at 31 March 2026, the Company reported a net total equity position of $53,803 (2025: $348,398) and negative

operating cash flows of $269,849 (2025: $432,856).


Page 22 Iperion Limited Annual Report 31 March 2026

16. GOING CONCERN - Continued

The Company is party to a Pilot Outsourcing Agreement, dated 2 September 2022, as part of Iperion’s strategy for

the commercialisation of the rights granted under the license agreement to manufacture and supply a self-

cleaning, antimicrobial, surface coating product. In accordance with the terms of the agreement, the Company

will pay fixed fees of NZD$400,000 per annum towards the rent and operation of the facility as well as

commission of 30% on gross sales. Invoices under the Pilot Outsourcing Agreement are payable in 30-day

instalments. Subsequent to year end, the Vendor has agreed to fully discount the agreed $400,000 fixed annual

fees until 31 March 2028.

Under the terms of the license agreement is a commitment for Iperion to achieve revenue of SGD$150,000 by

September 2026. Subsequent to year end, the parties have agreed that the customers number and revenue

performance targets under the license agreement be permanently waived. Iperion has the ability to terminate

the Pilot Outsourcing Agreement at any time, with prior notice to the Licensor, with no break fees. .

Subsequent to year end, Mr Chang Ku EE, a director and the majority shareholder of Iperion, confirmed that he

will provide financial support to the Company, if required to meet its working capital obligations and liabilities as

they fall due, for at least a period of 12 months from the date of approval of the Company’s financial statements.

Subsequent to year end, the company entered into a loan agreement with Mr EE pursuant to which Mr EE has

agreed to lend NZ$150,000 to the Company. The loan is interest-free and unsecured. The loan is repayable on

demand; however, Mr EE may only make a demand for repayment with the prior written agreement of the

Company's board of directors (excluding Mr EE). The Company may repay the loan, or any part of it, at any time

without penalty. The loan was subsequently replaced by a loan agreement with Elitesoft Asia Sdn. Bhd., a related

company to Mr Chang Ku EE. The loan with Elitesoft provides a loan facility of $250,000, that may be increased

to US$1,000,000 subject to shareholder approvals required under applicable law and NZX Listing Rules. The

facility is unsecured and available for working capital purposes.

The directors' cash flow forecasts assume that funding under the Elitesoft facility will be available to the Company

if required. The Company has not drawn on the full facility as at the date of approval of these financial

statements. The availability of the facility is dependent on the lender continuing to honour its funding

commitment.

Based on approved base case forecasts, which assumes no sales and assumes access to the Elitesoft facility of

$250,000, the Company expects to have sufficient liquidity to meet its forecast obligations over the next 12

months. The production processes are new and the product is new to the market and therefore uncertainty

remains regarding future sales volumes, sales margins and the timing of achieving profitable operations.

The directors have also considered that known expenditure can be managed through existing cash resources, the

agreed discount to fixed fees under the Outsourcing Agreement through to 31 March 2028, and the ability to

terminate the service agreement should sales and profitability objectives not be achieved.

However, if unplanned costs are incurred, sales do not eventuate or the agreement is not terminated in sufficient

time to manage cash flow, there is a risk that the business does not have sufficient funds to meet obligations as

and when they fall due. These factors represents material uncertainties that may cast significant doubt on the

Company’s ability to continue as a going concern. If the Company is unable to continue as a going concern, the

consequence is that Iperion may be unable to realise its assets and discharge its liabilities in the normal course of

business.


Page 23 Iperion Limited Annual Report 31 March 2026

17. SIGNIFICANT EVENTS AFTER REPORTING DATE

Subsequent to year end, Three Summit Ventures agreed to permanently waive the customer number and

revenue performance targets (note 15) and to fully discount the annual fixed fee of $400,000 until March 2028.

Subsequent to year end, the company entered into a loan agreement with Mr Chang Ku EE, a director of the

Company, pursuant to which Mr EE has agreed to lend NZ$150,000 to the Company. The loan is interest-free and

unsecured. The loan is repayable on demand; however, Mr EE may only make a demand for repayment with the

prior written agreement of the Company's board of directors (excluding Mr EE). The Company may repay the

loan, or any part of it, at any time without penalty. The loan was subsequently replaced by a loan agreement

with Elitesoft Asia, a related company to Mr Chang Ku EE. The loan with Elitesoft provides a loan facility of

$250,000, that may be increased to US$1,000,000 subject to shareholder approval. The repayment terms are

unchanged from the original $150,000 loan and the loan is unsecured, but an interest rate of Hong Kong

Monetary Authority Base Rate + 4% applies.


Page 24



BDO Auckland


INDEPENDENT AUDITOR’S REPORT

TO THE SHAREHOLDERS OF IPERION LIMITED



Opinion


We have audited the financial statements of Iperion Limited (“the Company”), which comprise the

statement of financial position as at 31 March 2026, and the statement of profit or loss and other

comprehensive income, statement of changes in equity and statement of cash flows for the year

then ended, and notes to the financial statements, including material accounting policy

information.


In our opinion, the accompanying financial statements present fairly, in all material respects, the

financial position of the Company as at 31 March 2026, and its financial performance and its cash

flows for the year then ended in accordance with New Zealand equivalents to International

Financial Reporting Standards (“NZ IFRS”) and IFRS

®

Accounting Standards.


Basis for Opinion


We conducted our audit in accordance with International Standards on Auditing (New Zealand)

(“ISAs (NZ)”). Our responsibilities under those standards are further described in the Auditor’s

Responsibilities for the Audit of the Financial Statements section of our report. We are

independent of the Company in accordance with Professional and Ethical Standard 1 International

Code of Ethics for Assurance Practitioners (including International Independence Standards) (New

Zealand) issued by the New Zealand Auditing and Assurance Standards Board, and we have fulfilled

our other ethical responsibilities in accordance with these requirements. We believe that the audit

evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Other than in our capacity as auditor we have no relationship with, or interests in, the Company.


Material Uncertainty Related to Going Concern


We draw attention to Note 16 of the financial statements, which indicates that the Company

incurred a net loss of $294,595 during the year ended 31 March 2026 (2025: $455,683) and, as at

that date, had net assets of $53,803 (2025: $348,398), and negative operating cash flows of

$269,849 (2025: $432,856). The Company has not yet generated revenue from the

commercialisation of Pathoglaze and, while commercialisation activities continue, uncertainty

remains regarding the timing of sales conversions and the level of future sales volumes and margins

that the product will achieve.


As disclosed in Note 16, subsequent to year end the Company obtained a $250,000 loan facility from

a related party and received confirmation of ongoing financial support from its majority

shareholder to assist the Company in meeting its obligations as they fall due. In addition, the

counterparty to the Pilot Outsourcing Agreement agreed to waive the annual fixed fees under that

agreement until 31 March 2028 and certain performance targets under the licence agreement have

been permanently waived. As stated in Note 16, these events or conditions, along with other

matters as set forth in Note 16, indicate that a material uncertainty exists that may cast significant

doubt on the Company’s ability to continue as a going concern. Our opinion is not modified in

respect of this matter.






Page 25



BDO Auckland


Key Audit Matters


Key audit matters are those matters that, in our professional judgement, were of most significance

in our audit of the financial statements of the current period. These matters were addressed in the

context of our audit of the financial statements as a whole, and in forming our opinion thereon,

and we do not provide a separate opinion on these matters. We have determined that other than

the matter described in the Material Uncertainty Related to Going Concern section, there are no

key audit matters to be communicated in our report.


Other Information


The directors are responsible for the other information. The other information comprises the

Annual Report, but does not include the financial statements and our auditor’s report thereon.


Our opinion on the financial statements does not cover the other information and we do not express

any form of audit opinion or assurance conclusion thereon.


In connection with our audit of the financial statements, our responsibility is to read the other

information and, in doing so, consider whether the other information is materially inconsistent with

the financial statements or our knowledge obtained in the audit or otherwise appears to be

materially misstated. If, based on the work we have performed, we conclude that there is a

material misstatement of this other information, we are required to report that fact. We have

nothing to report in this regard.


Directors’ Responsibilities for the Financial Statements


The directors are responsible on behalf of the Company for the preparation and fair presentation of

the financial statements in accordance with NZ IFRS and IFRS

®

Accounting Standards, and for such

internal control as the directors determine is necessary to enable the preparation of financial

statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible on behalf of the Company for

assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters

related to going concern and using the going concern basis of accounting unless the directors either

intend to liquidate the Company or to cease operations, or have no realistic alternative but to do

so.


Auditor’s Responsibilities for the Audit of the Financial Statements


Our objectives are to obtain reasonable assurance about whether the financial statements as a

whole are free from material misstatement, whether due to fraud or error, and to issue an

auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is

not a guarantee that an audit conducted in accordance with ISAs (NZ) will always detect a material

misstatement when it exists. Misstatements can arise from fraud or error and are considered

material if, individually or in the aggregate, they could reasonably be expected to influence the

decisions of users taken on the basis of these financial statements.


A further description of our responsibilities for the audit of the financial statements is located at

the External Reporting Board’s website at: https://www.xrb.govt.nz/assurance-standards/auditors-

responsibilities/audit-report-2/.


This description forms part of our auditor’s report.



Page 26



BDO Auckland


Who we Report to


This report is made solely to the Company’s shareholders, as a body. Our audit work has been

undertaken so that we might state those matters which we are required to state to them in an

auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept

or assume responsibility to anyone other than the Company and the Company’s shareholders, as a

body, for our audit work, for this report or for the opinions we have formed.


The engagement partner on the audit resulting in this independent auditor’s report is Junita Sen.





BDO Auckland

Auckland

New Zealand

30 June 2026



Page 27 Iperion Limited Annual Report 31 March 2026

CORPORATE GOVERNANCE STATEMENT

The Board of Directors (“Board”) of Iperion (“IPR”) recognise the need for strong corporate governance practices

and has adopted a comprehensive corporate governance code. The code is based on the recommendations set

out in the NZX Corporate Governance Code and the requirements of the NZX Main Board Listing Rules. The

Company’s website is currently under construction; but in the interim copies of key documents referred to in this

section can be requested by emailing john.cilliers@outlook.co.nz. The information contained in this section is

current as at 24 June 2026 and has been approved by the Board. The key documents within the code were last

reviewed effective June 2026 and a summary statement of the key documents is as follows:

Code of Ethics and Financial Products Trading Policy

Iperion has adopted policies that are designed to formalise its commitment to the highest standards of ethical

conduct and to provide all Directors and representatives with clear guidance on those standards. These are

governed by the Code of Ethics and also the Financial Products Trading Policy.

The Code of Ethics details the ethical and professional behavioural standards required of the Directors and all

employees.

The Financial Products Trading Policy details the procedure whereby Iperion Directors and employees may trade

in the Company’s shares. Directors and employees may not trade in Iperion shares when they have price sensitive

information that is not publicly available. In addition, except where the Directors have the permission of the

Board, the Directors may trade in the Company’s shares only during specified trading windows.

The Company maintains an interests register in which the particulars of certain transactions and matters involving

Directors must be recorded. Details of all matters entered into the register by individual Directors are outlined in

Note 13 of the Financial Statements.

Governance Code

The Board has adopted a Governance Code that sets out the roles and responsibilities of the Board and

distinguishes between the role and responsibilities of the Board and Management. Board's role is to direct the

Company and enhance its value for Shareholders in accordance with good governance principles. The Board

recognises that the quality with which it performs its functions is an integral part of the performance of the

Company and that there is a strong link between good governance and performance.

Role and Composition of the Board

Iperion retains a Board of Directors which aims to ensure that shareholders’ interests are held paramount. The

Board is responsible for the direction and control of Iperion and is accountable to shareholders and others for the

Company’s performance and compliance with the appropriate laws and standards. A key responsibility of the

Board is to monitor the performance of management on an ongoing basis.

The Company’s Constitution requires a minimum of three Directors with a maximum of seven. At least two of the

Directors must be ordinarily resident in New Zealand. The composition of the Board must include a minimum of

two Independent Directors. The Board elects a Chairman whose primary responsibility is the efficient functioning

of the Board. The Board is currently made up of four Directors and the Board considers that two Directors are

independent in terms of the New Zealand Exchange requirements.


Page 28 Iperion Limited Annual Report 31 March 2026

Independent Directors

• Bruce Dunlop

• John Cilliers

Director

• Chang Ku EE (Chairman)

• Kuan Chong NG


Board meetings

The Board met regularly during the year. The Board is provided with accurate timely information on all aspects of

the Company’s operations. The Board is kept informed of key risks to the Company on a continuing basis. In

addition, the Board meets whenever necessary to deal with specific matters needing attention between the

scheduled meetings.

The table below shows director attendance at board meetings during the year ended 31 March 2026:

Chang Ku EE (Chairman) -

Kuan Chong NG 10

John Cilliers 10

Bruce Dunlop 10

Diversity Policy

Iperion believes that diversity and inclusion contribute to competitive advantage and sustainable business

success which is reflected in the Companies Diversity Policy. Iperion is committed to an inclusive workplace that

fosters and promotes workplace diversity at all levels. This provides the capacity to view problems and

opportunities from many different perspectives.

Board diversity table as at 31 March 2026:

4 male directors

0 female directors

0 gender diverse directors

0 male officers

0 female officers

0 gender diverse officers

The Board believes that the current makeup of the Board is appropriate at this time.

Board Committees – Audit Finance and Risk Committee

The Board has overall responsibility for the Company’s system of risk management and internal control. The

Board has established a Committee known as the Audit, Finance and Risk Committee. The primary purpose of the

Audit, Finance and Risk Committee is to assist the Board of Iperion in fulfilling its responsibilities relating to the

company’s management systems, accounting and reporting, external and internal audit, finance and risk

management activities. The Committee comprises John Cilliers (Chairman of Committee), Bruce Dunlop and KC

Ng. Meetings are held not less than twice a year having regard to the Company’s reporting and audit cycle.


Page 29 Iperion Limited Annual Report 31 March 2026

Management tools used by Iperion include the audit committee function, outsourcing of certain functions to

experts, internal controls, financial and compliance reporting procedures and processes, business continuity

planning and insurance.

Other Committees

Due to the importance of Nomination and Remuneration matters these are addressed by the Board as a whole

and consequently there is no separate Nomination or Remuneration Committee at this time.

Continuous Disclosure

Iperion’s Market Disclosure Policy sets out the Company’s arrangements to ensure material information is

identified, reported, assessed and, where required, disclosed to the market in a timely manner. Iperion is

committed to ensuring the timely disclosure of material information about the Company to ensuring that the

Company complies with the NZX Main Board Listing Rules.

Remuneration Policy

Iperion’s Remuneration Policy is included in its Remuneration, Nomination and Health & Safety Committee

Charter which sets out the principles which apply to the remuneration of the Board and employees. Details of

individual director remuneration are outlined on page 30 and in Note 13 of the Financial Statements.

Auditors

The Audit, Finance and Risk Committee is accountable for ensuring the performance and independence of the

external auditors – BDO Auckland. The Committee also recommends to the Board, which services other than the

statutory audit, may be provided by BDO Auckland as auditors.

Shareholder Relations

The Board recognises the importance of providing comprehensive and timely information to shareholders.

Information is communicated to shareholders in the Interim Report and the Annual Report. The release of the

Annual Report is followed by the Annual Shareholders Meeting, which the Board recognises as an important

forum at which the shareholders can meet and question the Board. Full participation of shareholders is

encouraged at the Annual Shareholders Meeting to ensure a high level of accountability and identification with

the Company’s strategies and goals. Shareholders are encouraged to submit questions in writing prior to the

meeting.

Environmental, Social and Governance

Iperion recognises the importance of minimising our environmental, social and governance impact. The Company

is committed to minimise its environmental impact and achieve sustainable business practices.

Summary of Exceptions

The Company’s corporate governance code is based on the recommendations set out in the NZX Corporate

Governance Code and the requirements of the NZX Main Board Listing Rules. The Board considers that Iperion’s

corporate governance code has followed these recommendations and requirements in all material respects in the

current year with the following exceptions:


Page 30 Iperion Limited Annual Report 31 March 2026

• Recommendation 3.6 (protocols setting procedure to follow if takeover offer received including the set-

up of a separate committee) - there are no written protocols at this time but the whole Board would be

immediately involved and legal advice sought.

• Recommendation 4.4 (reporting includes non-financial disclosures such as exposure to environmental

risks and how those risks are managed) – due to the Company’s limited current operations such

reporting will be considered in future years.

• Recommendation 8.5 (the board should ensure that the notices of annual or special meetings of quoted

equity security holders is posted on the issuer’s website as soon as possible and at least 20 working days

prior to the meeting) - the Company held the 2025 Annual Meeting on 26 September 2025. The notice

of the Annual Meeting was released on 29 August 2025, being less than the 20 working days

recommended.

The alternate governance practices described above have been approved by the Board.



Page 31 Iperion Limited Annual Report 31 March 2026

ADDITIONAL INFORMATION

STOCK EXCHANGE LISTING

Iperion Ltd is listed on NZSX under the code IPR for ordinary shares.

REGISTRY

Link Market Services is Iperion’s security register manager and holds all shareholder records electronically. Link

Market Services is also responsible for the maintenance of shareholder records, Iperion’s call centre, and the

preparation of distribution payments. Contact details for Link Market Services are set out in the business

directory on the last page.

ANNUAL REPORT AND ANNUAL MEETING

All shareholders are entitled to receive a copy of the Annual Report. If you do not require the Annual Report, or if

you receive more copies than you require, please notify Link Market Services at the address shown on the last

page.

The next Annual General Meeting is intended to be held in September 2026. The Notice of Meeting and Proxy

Form will be sent shortly.

PRINCIPAL ACTIVITIES AND CHANGES IN STATE OF AFFAIRS

The Company is currently in the process of commercialisation of novel antimicrobial compounds.

DIRECTORS

The following directors held office during the financial year:

Current directors:

Chang Ku EE

Kuan Chong NG

John Cilliers

Bruce Dunlop


DIRECTORS INTEREST IN IPERION LIMITED

The following table sets out each current director’s relevant interest (direct and indirect) in shares of the

company as at the date of this report.


Directors

Fully paid

ordinary

shares

%

Chang Ku EE398,528,343 77.40%

John Ci l l i ers50,000 0.01%


Page 32 Iperion Limited Annual Report 31 March 2026

REMUNERATION

The following table provides the compensation for key management personnel and directors.


During the financial year there were no employees or former employees who received remuneration and other

benefits in their capacity as employees of the Company of which was or exceeded $100,000 per annum.

The Board received no notice during the year from directors requesting to use the Company information received

in their capacity as directors which would not have been otherwise available to them.


DIRECTORS DISCLOSURE OF INTERESTS

The following general disclosures of interest were received in relation to the year ended 31 March 2026:

Chang Ku EE

John Cilliers

• ESA Holdings Limited


• Incrementum Ltd

• C&T Graphics


• Acanthus Ltd



• Arlen Management Ltd

Kuan Chong NG


• Callisto One Ltd

• Iperion TSV Services


• Myland Partners NZ Ltd



• Soloura Ltd

Bruce Dunlop


• Vineway Ltd

• Pracsol Limited


• Western City Holdings Ltd

Director fees

Professional

services fees

Other

employee

benefits

Total

$

$

$

$

Chang Ku EE

48,000



-



-



48,000



Kuan Chong NG

36,000



36,000



-



72,000



John Cilliers

36,000



6,737



-



42,737



Bruce Dunlop

36,000



-



-



36,000



156,000



42,737



-



198,737



2026


Page 33 Iperion Limited Annual Report 31 March 2026

DISTRIBUTION OF SECURITY HOLDERS (AS AT 15 JUN 2026)



20 LARGEST SHAREHOLDERS (AS AT 15 JUN 2026)


Distribution of Secutiry Holders

Size of Holding

Number

%

Number

%

1-1000

358



74.1%

196,000



0.04%

1001-5000

16



3.3%

39,200



0.01%

5001-10000

16



3.3%

139,495



0.03%

10001-50000

28



5.8%

677,592



0.13%

50001-100000

14



2.9%

1,161,632



0.23%

Greater than 100000

51



10.6%

512,680,581



99.57%

483



100.0%

514,894,500



100.00%

Number of Securities

Number of Security Holders

Ordinary shareholdersNumber%

1Chang Ku Ee398,528,343 77.4%

2Kycz Limited44,280,927 8.6%

3Trinity Portfolio Limited9,000,000 1.8%

4Jo Ro Co Limited8,405,130 1.6%

5Robert Gregory Mcauley7,464,312 1.5%

6Roger Grice7,459,505 1.5%

7Uob Kay Hian Private Limited5,247,406 1.0%

8Russell Maloney5,015,092 1.0%

9John Sydney Philpott4,938,425 1.0%

10Lei Pei4,000,000 0.8%

11Global Paradigm2,785,714 0.5%

12Murray Horton Blackwell2,576,400 0.5%

13Custodial Services Limited2,188,212 0.3%

14Richard Black1,540,754 0.2%

15Betalert Limited668,596 0.2%

16Parminder Kumar Sharma617,750 0.1%

17M F Campbell Limited600,000 0.1%

18Christopher David Castle579,432 0.1%

19Philip Stickland500,000 0.1%

20Graeme Craig Joynt500,000 0.1%

21R & K Famularo Family413,425 0.1%

507,309,423 98.42%

Fully paid


Page 34 Iperion Limited Annual Report 31 March 2026

SUBSTANTIAL SHAREHOLDERS

As at 31 March 2026, the following holders are Substantial Product Holders in Iperion within the meaning of that

expression under Section 274 of the Financial Markets Conduct Act 2013:


VOTING RIGHTS

Under the Company’s Constitution, each member present at a general meeting is entitled:

1. on a show of hands, to one vote; and

2. on a poll, to one vote for each share held or represented.

WAIVERS

There were no waivers granted or published by the NZX in relation to Iperion or relied upon by the Company in

the 12 month period to 31 March 2026.

AUDIT FEE

Auditor’s fees are disclosed in note 3 of the financial statements.

DONATIONS

No donations were made during the year.

ANNUAL REPORT CERTIFICATE

This Annual Report is dated 30 June 2026 and is signed on behalf of the Board by:



Director: Bruce Dunlop Director: John Cilliers


HolderShares held%Classification of holding

Chang Ku Ee398,528,343 77.4%Regi stered hol der and benefi ci al owner

KYCZ Li mi ted44,280,927 8.6%Regi stered hol der and benefi ci al owner


Page 35 Iperion Limited Annual Report 31 March 2026


BUSINESS DIRECTORY


Company

number:

4844319


Directors:

Chang Ku EE, Chairman

Kuan Chong NG

John Cilliers

Bruce Dunlop


Registered

office:

Level 2 Tower Building

50 Customhouse Quay

Wellington, 6011

New Zealand


Share Registrar


Link Market Services

Level 7, Zurich House

21 Queen Street

Auckland 1010


Bankers:

Westpac Bank Limited


Solicitors:

Duncan Cotterill

Wellington


Auditors:

BDO Auckland

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.